Ischemic heart disease (IHD), which includes heart failure (HF) induced by heart attack (myocardial infarction, MI), is a significant cause of morbidity and mortality worldwide (Benjamin, et al. Circulation 139:e56–e66, 2019). MI occurs at an alarmingly high rate in the United States (approx. One case every 40 seconds), and the failure to repair damaged myocardium is the leading cause of recurrent heart attacks, heart failure (HF), and death within 5 years of MI (Benjamin, et al. Circulation 139:e56–e66, 2019). At present, HF represents an unmet need with no approved clinical therapies to replace the damaged myocardium. As the population ages, the number of heart failure patients is projected to increase, doubling the annual cost by 2030 (Benjamin, et al. Circulation 139:e56–e66, 2019). In the past decades, stem cell therapy has become a promising strategy for cardiac regeneration. However, stem cell-based therapy yielded modest success in human clinical trials. This chapter examines the types of cells examined in cardiac therapy in the setting of IHD, with a brief introduction to ongoing research aiming at enhancing the therapeutic potential of transplanted cells.
|Title of host publication||Advances in Experimental Medicine and Biology|
|Number of pages||19|
|State||Published - 2019|
|Name||Advances in Experimental Medicine and Biology|
Bibliographical notePublisher Copyright:
© Springer Nature Switzerland AG 2019.
- Bone marrow mononuclear cells
- Heart failure
- Mesenchymal stem cells
- Myocardial infarction
- Skeletal myoblasts
- Stem cells
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology (all)